RT Journal Article
SR Electronic
T1 Immunogenicity of BNT162b2 vaccine Against the Alpha and Delta Variants in Immunocompromised Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.08.21261766
DO 10.1101/2021.08.08.21261766
A1 Hadjadj, Jérome
A1 Planas, Delphine
A1 Ouedrani, Amani
A1 Buffier, Solene
A1 Delage, Laure
A1 Nguyen, Yann
A1 Bruel, Timothée
A1 Stolzenberg, Marie-Claude
A1 Staropoli, Isabelle
A1 Ermak, Natalia
A1 Macraigne, Laure
A1 Morbieu, Caroline
A1 Henriquez, Soledad
A1 Veyer, David
A1 Péré, Hélène
A1 Casadevall, Marion
A1 Mouthon, Luc
A1 Rieux-Laucat, Frédéric
A1 Chatenoud, Lucienne
A1 Schwartz, Olivier
A1 Terrier, Benjamin
YR 2021
UL http://medrxiv.org/content/early/2021/08/09/2021.08.08.21261766.abstract
AB Background The emergence of strains of SARS-CoV-2 exhibiting increase viral fitness and immune escape potential, such as the Delta variant (B.1.617.2), raises concerns in immunocompromised patients. To what extent Delta evades vaccine-induced immunity in immunocompromised individuals with systemic inflammatory diseases remains unclear.Methods We conducted a prospective study in patients with systemic inflammatory diseases (cases) and controls receiving two doses of BNT162b2. Primary end points were anti-spike antibodies levels and cross-neutralization of Alpha and Delta variants after BNT162b2 vaccine. Secondary end points were T-cell responses, breakthrough infections and safety.Results Sixty-four cases and 21 controls not previously infected with SARS-CoV-2 were analyzed. Kinetics of anti-spike IgG and IgA after BNT162b2 vaccine showed lower and delayed induction in cases, more pronounced with rituximab. Administration of two doses of BNT162b2 generated a neutralizing response against Alpha and Delta in 100% of controls, while sera from only one of rituximab-treated patients neutralized Alpha (5%) and none Delta. Other therapeutic regimens induced a partial neutralizing activity against Alpha, even lower against Delta. All controls and cases except those treated with methotrexate mounted a SARS-CoV-2 specific T-cell response. Methotrexate abrogated T-cell responses after one dose and dramatically impaired T-cell responses after 2 doses of BNT162b2.Conclusions Rituximab and methotrexate differentially impact the immunogenicity of BNT162b2, by impairing B-cell and T-cell responses, respectively. Delta fully escapes the humoral response of individuals treated with rituximab. These findings support efforts to improve BNT162b2 immunogenicity in immunocompromised individuals (Funded by the Fonds IMMUNOV; ClinicalTrials.gov number, NCT04870411).Competing Interest StatementTB, IS and OS are coinventors on provisional patent no US 63/020,063 entitled: S-Flow: a FACS-based assay for serological analysis of SARS-CoV-2 infection, submitted by Institut Pasteur.Clinical TrialNCT04870411Funding Statement-This study was supported by the Fonds IMMUNOV, for Innovation in Immunopathology. Work in OS lab is funded by Institut Pasteur, Urgence COVID-19 Fundraising Campaign of Institut Pasteur, Fondation pour la Recherche Medicale, ANRS, the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), ANR/FRM Flash Covid PROTEO-SARS-CoV-2 and IDISCOVR. DP is supported by the Vaccine Research Institute"Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The prospective COVADIS study (NCT04870411) was conducted in patients with systemic inflammatory diseases managed in the Internal Medicine department from Cochin Hospital, University of Paris (Paris, France). Authority for Health, considering either their immunocompromised status or their occupational exposure risk. Ethics approval was obtained by Comite de Protection des Personnes Nord-Ouest II. Cases and controls provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available by sending email to Pf Benjamin Terrier: benjamin.terrier{at}aphp.fr